We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Biomarker Detects Cardiac Event Immediately

By LabMedica International staff writers
Posted on 12 Jan 2012
A biomarker has been used to identify patients that have experienced a heart attack, enabling physicians to undertake aggressive treatment immediately.

The diagnostic performance of newly developed highly sensitive troponin I (hsTnI) assay was compared with a contemporary troponin I (cTnI) assay and their serial changes in the diagnosis of heart attack.

Scientists at the University Heart Center (Hamburg, Germany) studied a cohort of 1,818 patients with suspected acute coronary syndrome, conditions such as heart attack or angina. More...
The patients were enrolled in the study at chest pain units in Germany from 2007 to 2008. Twelve biomarkers including hsTnI and cTnI were measured on admission and six hours later. Heart attacks are clear in the public perception, and hospital admission for chest pains are one of the most common complaints. Highly sensitive troponin assays have been developed recently, and these tests can reliably assess troponin levels in more than 50% of the general population.

For the cTnI assay, the Architect STAT troponin I assay was used. The level of detection was 10 pg/mL, with a range of 0-50,000 pg/mL. The 99th percentile and the concentration with coefficient of variation of 10% is 32 pg/mL. The diagnostic threshold for myocardial infarction (MI) according to the World Health Organization's (Geneva, Switzerland) definition was given as 300 pg/mL by the manufacturer (Abbott Diagnostics, Abbott Park, IL, USA). The same manufacturer's prototype cardiac troponin I assay (Architect STAT High Sensitive Troponin) was used for hsTnI assay. For this assay, the level of detection is 3.4 pg/mL with a range, 0-50,000 pg/mL and the coefficient of variation is 10% at a concentration of 5.2 pg/mL.

For discrimination of acute MI, both hsTnI and cTnI were superior to the other evaluated diagnostic biomarkers. Using the 99th percentile cutoff, hsTnI on admission had a sensitivity of 82.3 % and negative predictive value (NPV) of 94.7%; hsTnI determined after three hours had a sensitivity of 98.2% with NPV of 99.4%. Compared with hsTnI, the cTnI assay, using the 99th percentile as cutoff had comparable sensitivity and NPV: 79.4% sensitivity and 94.0% NPV on admission, and 98.2% sensitivity and 99.4% NPV after three hours.

Till Keller, MD, a senior author of the study, concluded that "The shortcoming of conventional troponin assays with low sensitivity within the first hours after chest pain onset led to the evaluation of various so-called early biomarkers in the diagnosis of MI. In our study, the diagnostic information of hsTnI was superior to all other evaluated biomarkers alone." The study was published on December 28, 2011, in the Journal of the American Medical Association (JAMA).

Related Links:

University Heart Center
Abbott Diagnostics
World Health Organization




Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
Collection and Transport System
PurSafe Plus®
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.